Category: ACN Newswire

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 领先电子产品生产商华讯股份有限公司（「华讯」或「集团」）（股份代号：833）宣布其位于马来西亚槟城的生产基地正式启用。该新设施为集团多元制造布局策略的重要里程碑，标志着拓展中国内地以外产能，并进一步强化东南亚的生产网络。该槟城厂占地约60,000平方呎，设有12条生产线，每月产能达250,000至300,000件。该厂作为原始设备制造（OEM）生产基地，主要生产销往国际市场的工业电子产品、环境控制设备及电子电源模块。新增产能不仅扩大集团的整体制造规模，亦满足持续增长的市场需求，为未来业务拓展提供稳固基础。是次启用乃承接集团于2025年完成的多项策略性部署，包括收购位于马来西亚槟城及越南胡志明市的制造业务。进军马来西亚为集团首次在中国内地以外建立生产据点。集团于2025年8月完成收购槟城厂后，展开扩建及升级，引入先进设备及优化生产流程，以提升效率及质量管理水平。该设施现时生产灌溉传感器、恒温器、保安设备及锂电池组。华讯主席兼执行董事林贤奇先生表示：「槟城厂在推动集团建立更多元化制造网络的策略中发挥关键作用。配合越南业务的拓展，我们正持续强化生产能力，提升整体供应链的灵活性，有助进一步增强集团的韧性与应变能力，使我们能在瞬息万变的全球环境下更有效支持客户业务发展。」华讯行政总裁兼执行董事林子泰先生补充指：「槟城厂正稳步提升产能，并已承接现有及新客户的新增订单。随着生产线扩充及系统升级完成，产能将更趋充裕，以配合未来需求。集团亦正评估于马来西亚设立另一个具相若产能的生产基地，推动下一阶段的业务增长。」 马来西亚官方代表、华讯董事局成员及管理层于当地新厂房举行剪彩仪式。华讯马来西亚生产基地配备12条生产线，每月产能达250,000至300,000件，进一步扩大集团制造规模，满足持续增长的客户需求。有关华讯股份有限公司（股份代号：833）华讯股份有限公司主要从事设计及生产多款高质量且时尚的电子产品。本公司为明晟（「MSCI」）香港微型指数成份股。有关详情，请浏览网页http://www.alltronics.com.hk/。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月5日 - (亚太商讯 via SeaPRwire.com) - 君圣泰医药（股票代码：2511.HK），一家专注于心肾代谢系统疾病（CKM）、开发多功能多靶点疗法的创新生物医药公司，今日在英国格拉斯哥举行的第63届欧洲肾脏协会（ERA）年会上，以口头报告的形式公布了其核心产品HTD1801的肾脏保护最新研究结果。HTD1801是全球首创的靶向AMPK-NLRP3通路的抗炎代谢调节剂（AIMM）。在已完成的III期临床研究（SYMPHONY-1&2）中，HTD1801显著改善了基线eGFR为60–90 mL/min/1.73m²的2型糖尿病（T2DM）患者的肾功能。治疗52周后，这些患者的eGFR平均升高了+3.08 mL/min/1.73m²（95% CI: 0.46–5.70），且未出现高滤过或体液潴留。这些结果提示，HTD1801和现有机制药物有差异化优势，并具有延缓甚至逆转疾病进程的潜力。本项研究进一步解释了上述临床结果。该研究由君圣泰医药与中国医学科学院医药生物技术研究所蒋建东院士研究团队共同完成，结果显示，在葡萄糖及棕榈酸诱导的足细胞损伤模型中，HTD1801可显著提升足细胞存活率、抑制细胞凋亡；恢复足细胞关键结构蛋白nephrin与podocin的表达；并显著降低代谢性炎症通路中磷酸化NF-κB及凋亡执行蛋白caspase-3水平。在糖尿病肾病（DN）模型中，HTD1801可呈剂量依赖性改善肾脏组织结构，降低肾小管损伤评分，减轻肾脏炎症及纤维化病变，并显著降低24小时尿微量白蛋白水平。该研究系统性阐明HTD1801可抑制足细胞炎症与凋亡、稳定肾小球结构，进一步揭示了HTD1801的肾脏保护潜力，为其成为慢性肾病（CKD）及其他肾脏疾病的潜在疗法提供了重要的科学依据。摘要标题：HTD1801减轻足细胞凋亡与肾小球损伤--肾脏保护机理探析报告编号：2243报告时间：2026年6月4日，星期四，上午8:15（英国夏令时间）报告形式：口头报告报告人：Filip Surmont博士，君圣泰医药首席医学官君圣泰医药首席医学官Filip Surmont博士表示："此次研究首次从足细胞与肾小球层面揭示了HTD1801的肾脏保护作用。临床研究与临床前研究结果的高度一致，进一步证实了HTD1801在CKD或其他肾脏疾病中直击核心病理进程的能力，彰显了其重要治疗潜力。我们将持续推进HTD1801在CKD等适应症的临床开发，力求为全球肾病患者带来更多创新的治疗选择。"关于HTD1801HTD1801是一款全球首创的新分子实体，旨在解决心肾代谢系统疾病（CKM）的未满足临床需求。HTD1801作为单一分子，是具有独特双机制的口服抗炎及代谢调节剂（AIMM），通过激活AMPK及抑制NLRP3炎症小体发挥其生物学活性；这种互补协同的双机制作用可有效解决代谢问题。全球多项临床结果验证HTD1801具有"一药多效"的特性，能够为患者带来综合获益，包括改善胰岛素敏感性、血糖控制、血脂降低、肾脏保护、体重减轻、肝脏获益及抗炎等。基于此，HTD1801有潜力成为CKM领域的基础性治疗药物。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 5, 2026 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK.HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) targeting the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), HTD1801 demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m². Treatment of these patients with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These findings suggest that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.This study was conducted by HighTide Therapeutics in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and further explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. HTD1801 also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing the levels of the inflammatory marker phosphorylated NF-κB and the apoptosis executioner caspase-3. In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin.The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential. These findings provide important scientific rationale for the development of HTD1801 as a potential disease-modifying therapy for chronic kidney disease (CKD) and other renal diseases.Abstract Title: HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into RenoprotectionPresentation Number: 2243Presentation Date/Time: Thursday, June 4, 2026, 8:15 a.m. BSTFormat: Oral PresentationSpeaker: Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics“This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases,” said Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics. “We will continue advancing the clinical development of HTD1801 across CKD and related indications to provide more treatment options for patients worldwide.”About HTD1801HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 5, 2026 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) celebrated its 11th anniversary by hosting the annual Charity Golf & Gala Dinner at Sentosa Golf Club on 28 May 2026.The event, graced by Guest of Honour Mr Masagos Zulkifli, Minister for Social and Family Development, drew over 120 golfers from Singapore’s legal and professional community for a day of sports and philanthropy, culminating in a gala dinner that reaffirmed the Foundation’s enduring commitment to make a difference in the lives of those it serves. The event also marked the 15th anniversary of RHTLaw Asia LLP.The Foundation raised more than S$280,000 through the event to benefit four local charities, namely PCF Sparkle Care, Singapore Road Safety Council, Singapore Golf Association, and Bethel Community Services.In addition to the fundraising milestone, the evening saw a leadership transition within the Foundation. Ms Kaylee Kwok stepped down as Chairman with effect from 28 May 2026, having stewarded the Foundation through 4 years of sustained growth and deepening community impact.“It has been a great privilege to serve as Chairman of ONERHT Foundation. What began as a conviction that the legal and professional community could do more has grown into something truly meaningful, with over S$6 million raised, more than 40 beneficiaries supported, and countless lives touched across Singapore and the region. I am deeply grateful to our sponsors, donors, partners and our ONERHT colleagues for their strong support and commitment. I leave with full confidence that the Foundation’s best years are still ahead,” said Ms Kaylee Kwok.Mr Nandakumar Renganathan has been appointed as the new Chairman of ONERHT Foundation, also with effect from 28 May 2026. Mr Nandakumar brings with him a deep commitment to the Foundation’s mission and vision to extend its reach across Singapore and the broader ASEAN region.“I am deeply honoured to take on this role and equally grateful to Kaylee for her leadership and contributions to the Foundation. ONERHT Foundation stands for something bigger than any one of us, a belief that those of us in the legal and professional community have a responsibility to give back, not just once, but consistently and with purpose. I look forward to working with our sponsors, donors, partners and beneficiaries as well as our ONERHT colleagues to carry that mission forward and extend our reach even further across Singapore and ASEAN,” said Mr Nandakumar.The evening also witnessed the signing of a Memorandum of Understanding (MOU) between RHTLaw Asia and the Association for Persons with Special Needs (APSN), marking a new chapter in the Foundation’s commitment to building meaningful and lasting partnerships with the communities it serves. ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$6 million to support more than 40 beneficiaries involved in education, environmental protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationFor media enquiries, please contact:Melody OngEmail: melody@waterbrooks.com.sg+65 8901 9780General enquiries:Email: query@waterbrooks.com.sg+65 9338 8166 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Zhangjiakou, China, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - In the first half of 2026, SnowValley, China's leading frozen potato product manufacturer, showcased its products and solutions at 4 of the world's premier food industry events — Gulfood in the Middle East, FOODEX Japan, FHA Food & Beverage in Singapore, and THAIFEX-Anuga Asia in Thailand. Through its presence at these flagship exhibitions, SnowValley further strengthened its reach across key consumer markets in the Middle East, East Asia, and Southeast Asia.Leveraging these world's top food industry exhibitions, SnowValley showcased its integrated industrial chain competitiveness and global service capabilities, attracting widespread attention from industry professionals, international buyers, and leading media worldwide.Recognized for multiple consecutive years among the Top 500 Chinese Brands and Top 500 Asian Brands, SnowValley continues to strengthen its international brand presence through its localized market strategies and deep engagement with overseas distribution networks across multiple countries. By securing a series of cross-border strategic partnerships, the company is further expanding its worldwide network and reinforcing its position in the global frozen potato products industry.Throughout the exhibitions, SnowValley earned strong recognition and trust from global buyers by leveraging its highly standardized manufacturing system, market-driven product customization capabilities, and efficient & reliable global supply chain. Today, SnowValley offers a portfolio of more than 160 SKUs, with products exported to over 40 countries and regions worldwide.With years of dedication to the potato products industry, SnowValley has achieved an all-round internationalization upgrade spanning product exports, brand development, and industry-standard promotion, driven by quality and innovation as the core and supported by global operations.Looking ahead, SnowValley will continue to enhance its product R&D capabilities and expand its international presence. By delivering high-quality deep-processed potato products, SnowValley aims to empower the development of the global foodservice industry, promote the standardization and upgrading of the sector through leading quality, and continuously explore and create sustainable value within the global food supply chain.Company: SnowValley Food Hebei Co.,Ltd.Contact Person: Joyce YangEmail: sales@snowvalleyfood.comWebsite: https://snowvalleyfood.com/en/Telephone: +86 131 6429 9552City: Zhangjiakou, Hebei Province Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, June 4, 2026 - (ACN Newswire via SeaPRwire.com) - Managing money in a high-cost city like Singapore can feel complex, especially when multiple financial commitments run in parallel. From education expenses and medical bills to consolidating existing dues, Personal Loans in Singapore are often explored as a flexible financing option. When approached thoughtfully, they can help create breathing room in monthly cash flow and bring more structure to scattered payments. The key lies in understanding how these loans work in the local context and using them in ways that align with income patterns, interest rates, and realistic repayment timelines.Understanding how Personal Loans work in SingaporePersonal Loans in Singapore are unsecured loans, meaning they do not require collateral such as property or fixed deposits. Loan amounts can vary widely depending on income eligibility and lender criteria, subject to applicable regulatory requirements. Interest rates are often quoted as flat rates or effective interest rates (EIR), with EIRs commonly ranging between 2.65% and 3.75% per annum for salaried individuals. Understanding the difference between flat rates and EIRs, as well as how rates vary across lenders, can help borrowers estimate the actual cost of borrowing more accurately. Repayment tenures usually span from one to five years, offering flexibility to match monthly obligations with income cycles.Situations where Personal Loans may help improve cash flowPersonal Loans may be useful in specific scenarios where timing and predictability matter more than long-term borrowing. For instance, consolidating multiple high-interest payments into one structured loan can simplify finances and make monthly outflows easier to track. A consolidated single personal loan instalment per month may feel more manageable than juggling three or four smaller payments with varying due dates. Similarly, planned expenses such as professional certifications or home repairs may benefit from fixed monthly repayments rather than ad-hoc withdrawals from savings. This approach can help maintain liquidity while spreading costs over time.Using Personal Loans for Debt ConsolidationDebt consolidation is one of the more common reasons borrowers explore personal loans in Singapore, especially when dealing with credit card balances. For illustration purpose, credit cards may carry interest rates exceeding 25% per annum, which may strain monthly budgets if balances revolve. A Personal Loan with a materially lower EIR may help reduce the interest burden while providing a clear repayment end date. Over a three-year tenure, consolidating SGD 20,000 in outstanding balances may translate into more predictable instalments and less uncertainty around interest accumulation, depending on the applicable terms. This structured approach may help improve financial clarity without relying on short-term credit cycles.Practical tips to use Personal Loans thoughtfullyAlign the loan amount with a clear purposeBorrowing with a defined goal can help keep loan usage focused and intentional. Whether the aim is consolidating debt or funding a necessary expense, having a specific number in mind can prevent over-borrowing. In Singapore, lenders may offer higher limits based on income, but choosing only what is required can help keep monthly instalments comfortable. This approach may also reduce total interest paid over the loan tenure.Compare EIR, not just headline offersAdvertised rates can sometimes appear attractive, but the EIR provides a clearer picture of the total cost. Processing fees, early repayment charges, and administrative costs can influence the final amount paid. For example, a loan with a 3% flat rate can translate to an EIR closer to 5.5% once fees are factored in. Comparing EIRs across lenders can help identify options that fit better within monthly budgets.Choose a tenure that balances flexibility and affordabilityLonger tenures reduce monthly instalment amounts, but they also increase total interest paid. Shorter tenures may feel heavier on cash flow but can close the loan faster. Borrowers earning between SGD 4,000 and SGD 6,000 per month often opt for a two- to three-year tenure, as it balances instalment size with interest impact. Selecting a tenure that aligns with income stability can help maintain consistency in repayments.Understanding income-based borrowing limitsIn Singapore, borrowing limits for personal loans are typically tied to annual income levels and overall credit assessment. Individuals earning less than SGD 20,000 annually are generally subject to more restrictive unsecured credit caps, while those earning above SGD 30,000 may be eligible for higher unsecured credit limits, subject to the banks' internal credit assessments and applicable regulatory requirements. These guidelines are designed to encourage responsible borrowing without overextending financial capacity. Staying within these limits can help ensure that loan repayments remain proportionate to income, leaving room for savings and everyday expenses. This balance can support longer-term financial resilience rather than short-term relief.Building a healthier money outlook with structured repaymentsOne often overlooked benefit of personal loans is the predictability they bring to monthly planning. Fixed instalments can make it easier to map expenses, set aside savings, and track progress over time. Seeing a loan balance reduce each month steadily may also encourage better financial habits. In Singapore's fast-paced environment, this structure may help individuals stay focused on broader money goals while managing immediate needs. Over time, this clarity may contribute to improved confidence in handling finances.Making Personal Loans work for your financial contextUsing personal loans thoughtfully in Singapore can be a practical way to bring order to complex financial situations. When loan amounts, interest rates, and tenures are aligned with income and clear objectives, they can help improve cash flow and reduce financial stress. Rather than acting as a quick fix, personal loans can serve as a structured tool that supports better financial management. With careful comparison and realistic planning, they may fit into a broader strategy aimed at stability and long-term financial well-being.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB LtdContact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）宣布与北京天广实生物技术股份有限公司（以下简称"天广实"）达成商业化授权许可合作协议，获得倍捷欣(R)（MIL62，通用名：奥妥珠单抗β注射液）在亚太地区（东南亚、印度、韩国、澳大利亚、新西兰、中国香港、中国澳门及中国台湾地区）的临床开发及商业化权益。根据相关协议，云顶新耀将向天广实支付人民币2,300万元的首付款，以及最高不超过人民币1.86亿元的销售里程碑款。天广实可获得该产品在亚太地区的销售毛利额分成款项。此次合作将进一步强化云顶新耀在肾科及自身免疫疾病等领域的亚太市场布局，并与现有肾科管线形成协同效应。云顶新耀将依托已获验证的临床开发及商业化能力，加速推动倍捷欣(R)的市场准入与商业化进程，持续释放亚太区域的增长潜力，并推进公司在全球创新药市场的长期战略发展。倍捷欣(R)是天广实自主研发的创新型第三代CD20抗体药物。根据相关资料显示，该药物已于2026年2月在中国获批上市，用于治疗视神经脊髓炎谱系疾病（NMOSD），成为全球首款治疗该疾病的CD20抗体，也是中国在该领域的首款国产药物。倍捷欣(R)用于治疗原发性膜性肾病（PMN）的新药上市申请亦处于中国国家药监局的"优先审评审批"阶段，有望成为全球首款获批的PMN特效药物。此外，倍捷欣(R)正在进行的临床III期试验覆盖系统性红斑狼疮（SLE）以及滤泡性淋巴瘤（FL）多个治疗领域，并具备向其他自身免疫性疾病持续拓展的潜力。云顶新耀董事会主席吴以芳表示："我们非常高兴能与天广实就倍捷欣(R)达成此次合作。倍捷欣(R)不仅是全球首款获批治疗NMOSD的CD20抗体，也是一款具有差异化优势和广阔市场前景的创新药，在肾科及自身免疫疾病领域展现出显著的临床潜力。此次合作将进一步丰富云顶新耀在肾科及自身免疫领域的产品布局，并与现有管线形成良好的协同效应。依托公司已建立并持续强化的临床开发及商业化能力，我们有信心加速推进倍捷欣(R)在亚太地区的开发与商业化进程，推动其尽快惠及更多患者，让创新疗法更快转化为临床可及性，并进一步提升公司在亚太及全球创新药市场的影响力。"天广实总裁陈鲁宁表示："我们非常欣喜与云顶新耀达成倍捷欣(R)在亚太地区的合作。倍捷欣(R)作为全球首款获批治疗NMOSD的CD20靶向药物，也是潜在全球首款治疗PMN的特效药物，拥有非常出色的产品竞争力与市场潜力。自产品上市以来，倍捷欣(R)在中国大陆地区已经取得了优异的商业化成绩，此次合作将进一步强化倍捷欣(R)在整个亚太市场的商业化网络与品牌影响力，为中国大陆以外的更多肾科及自身免疫性疾病患者带来「欣」希望。"倍捷欣(R)目前已在肾科及多个自身免疫疾病领域展现出显著的临床及治疗价值，并具备广阔的适应症拓展潜力。其在NMOSD、PMN及SLE等疾病领域的持续布局与进展，有望为患者带来更多创新治疗选择。NMOSD是一种高复发率、高致残率的中枢神经系统自身免疫性疾病，多发于青壮年女性。该病通常为急性或亚急性起病，可迅速进展，约90%的患者在三年内经历复发，严重者可导致失明甚至瘫痪。倍捷欣(R)在单药治疗中显示出降低复发风险的显著优势，并在疗效数据中展现出优异表现，凸显其作为单药疗法的临床价值与治疗便利性。PMN是成人肾病最常见的病理类型，约30%-40% 的患者在5-15年内可能进展为终末期肾病。目前全球范围内尚无获批的特效药。临床III期研究显示，倍捷欣(R)单药治疗在临床完全缓解、免疫学完全缓解及临床缓解等各项指标上均展现出显著优势。此外，倍捷欣(R)具有良好的安全性和耐受性，并且给药周期便捷，患者初始治疗后，每六个月仅需进行一次静脉注射，可显著降低治疗负担，同时有助于提升长期依从性。SLE是一种慢性系统性自身免疫疾病，倍捷欣(R)目前处于临床III期研究阶段，具有24–28周的长给药间隔优势，可满足患者对长效治疗方案的临床需求，有望为SLE患者提供更优治疗选择。此次合作被视为云顶新耀提升肾科及自身免疫领域战略纵深的重要举措。随着倍捷欣(R)在PMN等适应症上的开发与商业化推进，公司肾科产品矩阵将得到进一步补充，并强化现有管线的协同效应。此外，业内普遍认为，未来数年中国创新药加速进入亚太市场将迎来重要发展机遇。凭借临床价值、可负担性及可及性方面的综合优势，中国创新药与亚太地区日益增长的医疗需求持续契合。云顶新耀近年来持续推进亚太区域战略布局，已逐步形成覆盖临床开发、市场准入及商业化运营的能力体系。通过引入倍捷欣(R)等具备差异化临床价值的创新产品，云顶新耀正进一步拓展区域产品组合及市场覆盖，推动公司肾科及自身免疫领域商业化价值的释放，并为亚太业务发展注入新的增长动能。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin(R) (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China. Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin(R) and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.Bejescin(R) (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. As shown in relevant sources, it was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin(R) is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.“We are delighted to collaborate with Mabworks on Bejescin(R). As the first CD20 antibody approved globally for NMOSD, Bejescin(R) has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin(R) across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”“We are thrilled to announce our partnership with Everest Medicines on Bejescin(R) across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin(R) possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin(R) has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin(R)’s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.”Bejescin(R) has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin(R) has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin(R) monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin(R) showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin(R) is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.This collaboration is regarded as an important strategic step for Everest Medicines to deepen its footprint in the nephrology and autoimmune disease areas. With the development and commercialization of Bejescin(R) in indications such as PMN, the company’s nephrology product portfolio will be further strengthened, enhancing the synergistic effects within its existing pipeline.In addition, there is a broad consensus in the industry that the coming years may represent an important window of opportunity for the accelerated adoption of innovative Chinese medicines into the Asia Pacific region. Chinese innovation is becoming increasingly competitive in clinical value, affordability and accessibility, with growing alignment to the needs of healthcare systems and patients across the region. In recent years, Everest Medicines has continuously advanced its regional strategy in Asia-Pacific, gradually building an integrated capability system covering clinical development, market access, and commercialization. By introducing innovative products with differentiated clinical value such as Bejescin(R), the company is further expanding its regional product portfolio and market coverage, realizing the commercial value of its nephrology and autoimmune disease businesses, and injecting new growth momentum into its Asia-Pacific operations. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月4日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）宣布与Travere Therapeutics, Inc.（NASDAQ: TVTX，以下简称"Travere Therapeutics"）达成独家授权许可与合作协议。根据协议，Travere Therapeutics将获得EVER001（希布替尼，civorebrutinib）除大中华区及部分东南亚国家以外区域的独家开发及商业化权益。此次合作将加EVER001的全球临床开发与商业化进程，为全球肾病患者带来创新治疗选择。根据协议，云顶新耀将获得1.125亿美元的首付款，以及在最多五个适应症上获得高达10.3亿美元的开发、注册及商业化里程碑付款。此外，基于EVER001的未来年度净销售额，云顶新耀将获得从高个位数至双位数百分比的分级特许权使用费。该交易将在满足特定交割条件及完成必要监管程序后完成交割。本次云顶新耀的合作方Travere Therapeutics是一家在纳斯达克上市（股票代码：TVTX）的美国生物制药公司，重点布局罕见肾小球疾病领域，尤其聚焦IgA肾病和局灶节段性肾小球硬化（FSGS），并在研用于同型半胱氨酸尿症（HCU）等罕见遗传代谢疾病的治疗项目。其核心产品FILSPARI®（sparsentan）是一种口服双重内皮素受体拮抗剂及血管紧张素II AT1受体拮抗剂，已获美国FDA批准用于治疗IgA肾病及FSGS，成为全球首个且唯一获批用于FSGS治疗的药物，进一步强化其在肾病治疗领域的领先地位。EVER001是一款新一代共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂，具备"一个可以开发多种适应症的药物（pipeline-in-a-product）"的开发潜力。与共价不可逆BTK抑制剂相比，EVER001作为一款潜在的同类最佳产品，在保持高活性的同时具有高选择性，避免持续抑制带来的毒副作用。近年来，云顶新耀凭借强大的临床开发能力，在全球多中心临床试验推进、自主研发管线临床验证及国际授权合作等方面取得了多项里程碑进展。在EVER001的临床开发中，云顶新耀此前公布用于治疗中国原发性膜性肾病（PMN）患者的1b/2a期临床研究数据显示，EVER001展现出快速、深度且持久的免疫学和临床缓解，停药后仍持续获益，安全性高，耐受性强。这些结果支持EVER001具有治疗以蛋白尿为特征的自身免疫性肾小球疾病的潜力。EVER001具备在多种免疫介导性肾小球疾病中的开发潜力，包括PMN、IgA肾病、微小病变性肾病（MCD）、FSGS及狼疮性肾炎等。这类疾病均与异常免疫反应引发的肾小球损伤相关，可导致蛋白尿和肾功能下降，严重时甚至可能发展至终末期肾病，需要透析或肾移植治疗。EVER001有望为全球逾1000万名相关患者提供新的治疗选择。据悉，Travere Therapeutics计划在PMN、免疫介导的FSGS及MCD等适应症中推进EVER001的临床开发，并有望进一步拓展至更多适应症领域。云顶新耀董事会主席吴以芳表示："我们非常高兴与Travere Therapeutics达成此次合作。这一合作将加速EVER001的全球开发与商业化进程，进一步释放其在自身免疫性肾脏疾病领域的临床潜力与商业价值，为全球患者带来更多创新治疗选择。作为公司自主研发的潜在同类最佳创新药物，EVER001已在原发性膜性肾病等自身免疫性肾脏疾病治疗中展现出积极潜力。凭借其差异化作用机制，EVER001具备拓展至多种自身免疫性肾脏疾病的潜力，持续释放其临床开发潜力。公司始终坚持‘BD合作+自主研发’双轮驱动战略，持续推进战略性业务拓展与自主研发，不断完善全球研发体系建设，持续提升在全球创新药领域的综合竞争力。Travere Therapeutics在美国已有获批的肾科产品，在肾病药物开发、注册及商业化方面积累了丰富经验与成熟能力。双方将充分发挥各自优势，共同推进EVER001在原发性膜性肾病、免疫介导的局灶节段性肾小球硬化及微小病变性肾病上的全球临床开发，为全球患者带来更多突破性治疗选择。"Travere Therapeutics总裁兼首席执行官Eric Dube博士表示："EVER001作为我们罕见肾病领域管线的重要战略性补充，具有高度协同价值，并有望成为覆盖多种免疫介导罕见肾病的同类最佳疗法。罕见肾病患者目前仍面临巨大的未满足临床需求。我们认为，在IgA肾病和FSGS领域已取得的阶段性进展，仅是这一治疗领域潜力释放的开始。Travere Therapeutics持续推动该领域的重要创新与突破，凭借在罕见肾病领域积累的深厚专业经验、成熟的研发与商业化能力，以及对患者的持续承诺，我们将不断推动创新，为患者带来更多突破性治疗选择。作为一款具有差异化优势的口服可逆BTK抑制剂，EVER001在原发性膜性肾病中已展现出令人鼓舞的概念验证数据，其作用机制可覆盖免疫介导的局灶节段性肾小球硬化、微小病变肾病等更多疾病领域。我们相信，EVER001将为罕见肾病患者带来更具重要意义的治疗突破，进一步推动该领域治疗格局的重塑。"此次云顶新耀与Travere Therapeutics的合作，进一步推动了EVER001的全球化进程，也是云顶新耀创新药价值进一步释放的体现。目前，云顶新耀已形成由耐赋康®、MT1013及EVER001组成的肾科产品矩阵，覆盖IgA肾病、继发性甲状旁腺功能亢进症（SHPT）及多种免疫介导性肾脏疾病。通过持续深化肾科领域战略布局，云顶新耀正加速全球布局，以创新疗法为更多患者提供可及、可靠的治疗方案。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 4, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.Travere Therapeutics, is a Nasdaq-listed US biopharmaceutical company (NASDAQ: TVTX) with a focus on the field of rare glomerular diseases, particularly targeting IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The company is also developing therapeutic programs for rare genetic metabolic diseases, such as homocystinuria (HCU). Its core product, FILSPARI®(sparsentan) is the first and only medicine approved by the FDA for the treatment of FSGS, further strengthening the company’s leading position in the renal therapy sector.Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. As an investigational oral, covalent reversible BTK inhibitor, civorebrutinib is designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney disease. Driven by strong clinical development capabilities, Everest Medicines has recently achieved several key milestones in global multi-center trials, in-house R&D pipeline validation, and international licensing partnerships. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. EVER001 possesses therapeutic development potential in multiple immune-mediated glomerular diseases, including PMN, IgA nephropathy, MCD, FSGS, and lupus nephritis. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. EVER001 is expected to offer a new treatment option for more than 10 million affected patients globally. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. “This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.”“Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.”This cooperation between Everest Medicines and Travere Therapeutics further propels the globalization of EVER001, reflecting the continued unlocking of the value of Everest Medicines innovative drugs. Currently, Everest Medicines has established a comprehensive renal product matrix inclding Nefecon®, MT1013, and EVER001, spanning indications such as IgA nephropathy, secondary hyperparathyroidism (SHPT), and a wide range of immune-mediated kidney diseases. By continuously deepening its strategic layout in nephrology, Everest Medicines is accelerating its global footprint to provide accessible and reliable treatment solutions for more patients through innovative therapies. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月3日 - (亚太商讯 via SeaPRwire.com) - 近日，香港科技大学（港科大）与苏州天瞳威视电子科技股份有限公司（CalmCar）正式签署战略合作协议，共同成立港科大物理AI科创中心（以下简称"科创中心"）。该中心将聚焦物理 AI 全栈技术突破，面向当前AI对物理世界规律理解不足、推演能力有限、行动决策缺乏可靠支撑等核心瓶颈，构建具备理解、预测、推演与决策能力的新一代物理AI技术底座，支撑自动驾驶、机械人、智能制造等战略性产业发展，助力香港成为国家物理AI创新的重要战略支点。多维度研究方向：从芯片到应用的全栈布局科创中心围绕物理AI前沿研究方向和核心应用场景，覆盖芯片与系统、基础模型与数据、隐私保护与安全治理等，通过探索及利用世界模型构建高保真策略验证与交互推演能力，让AI能够在虚拟环境中进行推演和学习，再将能力迁移到真实世界，从而显著提升AI在复杂开放环境中的泛化性、可解释性与系统可靠性，为广泛的智能应用构建长期技术底座。中心的目标打造全球物理AI创新战略枢纽，主导领域评测基准与开源平台，培养具有国际竞争力的物理AI人才。立足香港、服务国家"AI+"战略科创中心将积极服务国家"AI+"战略，以香港为立足点、粤港澳大湾区为腹地、全球为舞台，致力于成为亚太地区物理智能研究的战略高地与国际合作枢纽。中心将构建从基础研究到产业落地的端到端研究能力，为行业提供统一的技术标准和通用工具。同时，中心将依托香港的国际化优势和大湾区完备的产业链资源，加速科技成果转化，打造世界一流的物理智能研究创新中心。顶尖学术班底，筑牢科研基石科创中心由加拿大工程院院士、欧洲科学院外籍院士、IEEE Fellow、港科大计算机科学及工程学系讲座教授郭嵩教授出任主任，牵头主持各项工作。郭嵩教授长期深耕分布式计算、边缘AI及多模态大模型领域，致力于攻克AI在真实物理环境中的泛化性与可靠性难题，曾获计算机领域最高学术成就之一的IEEE Edward J. McCluskey技术成就奖，是该领域的国际领军学者。其领衔的普适智能实验室是扎根香港十年，已在物理世界建模、具身强化学习、边缘智能系统优化等领域积累了大量原创性成果，为科创中心的技术攻关奠定了坚实的理论根基。 郭嵩教授指出："我们首创的'物理对齐'技术，将生成式视频模型升级为可交互的世界模型，标志着AI从'看世界'迈向'动手改变世界'的新阶段。通过虚拟空间无限试错，我们为下一代自动驾驶的行为预测与安全规划提供了全新范式。"郑纬民先生在致辞中定调：物理AI将是继通用大模型之后的重要战略方向。随后，他主持了战略咨询委员会与科创中心的握手合影仪式，标志着该领域正式迈入产学研融合新阶段，寄望物理AI科创中心能够持续为国家人工智能战略贡献重要力量。科创中心特邀中国工程院资深院士、中国计算机学会第十届理事长、清华大学郑纬民教授领衔战略委员会，中国工程院外籍院士、英国皇家工程院院士、欧洲科学院院士、港科大首席副校长郭毅可教授作为中心的校方顾问，将为科创中心提供坚实支持；战略委员会其他顾问成员还包括；中国工程院外籍院士、加拿大皇家科学院院士、加拿大工程院院士、滑铁卢大学沈学民教授；加拿大皇家科学院院士、微软技术院士、微软亚洲研究院常务副院长、IEEE Fellow、ACM Fellow郭百宁博士；欧洲科学院院士、IEEE Fellow、ACM Fellow、洛桑联邦理工学院（EPFL）协理副校长David ATIENZA ALONSO教授。从感知迈向理解，驱动智能系统进化相较于依赖海量数据拟合的传统AI，物理AI更强调模型对真实世界动态规律与因果结构的理解。物理AI的发展，正推动智能系统从单纯的感知识别，向融合物理一致性的动态预测、交互推理与自主决策演进。世界模型作为实现物理AI的重要技术路径之一，通过构建环境的内部表征并进行前瞻性推演，为复杂场景中的策略学习与验证提供了仿真基础，有望增强系统在分布式场景中的泛化能力与行为可靠性。依托该物理AI科创中心，共同发起方天瞳威视将率先在智能驾驶领域应用相关技术展开实践，让智驾系统不仅能看见环境，更能理解物理因果，对交通场景的演化趋势进行想象，从而实现从感知向认知的持续演进。面向未来，科创中心将致力于与更多产业合作伙伴构建合作，在不同应用场景下实践和验证物理AI技术理念，推动世界模型的技术路径创新，促进物理AI关键技术与产业生态的持续融合发展。 揭牌仪式：政产学研领袖共同见证本次科创中心揭牌仪式汇聚政界领导、学界权威、产业领军代表与投资界精英，与港科大校方代表和天瞳威视创始团队共同出席、携手揭牌，香港特别行政区立法会（科技创新界）议员邱达根先生、广州市大湾区办常务副主任陈旭先生等重磅嘉宾亲临现场，全程见证科创中心揭幕。作为本次科创中心建设的核心战略合作方，Lion X Ventures全程深度参与中心筹备与生态搭建，依托自身产业资源、跨境布局与资本优势，为中心落地营运提供全方位支撑，筑牢长远发展根基。高规格的政产学研阵容，叠加头部投资机构的战略赋能，充分彰显科创中心起步的行业高度、资源厚度与战略价值，亦标志着以港科大物理AI技术引领、多方协同联动的创新产业生态体系，在大湾区正式启航、全新启程。 港科大-天瞳威视"物理AI科创中心"正式揭牌（从左至右依次为：HSBC香港区行政总裁伍杨玉如女士，香港特别行政区立法会（科技创新界）议员邱达根先生，港科大校董会成员、评议会主席、Madhead行政总裁曾建中先生，港科大计算机科学及工程学系主任周晓方教授，中国工程院院士、中国计算机学会前理事长、清华大学教授郑纬民教授，天瞳威视董事长兼CEO王曦先生，港科大首席副校长郭毅可教授，港科大副校长（研究及发展）郑光廷教授，港科大计算机科学及工程学系讲座教授、物理AI科创中心主任郭嵩教授，广州市大湾区办常务副主任陈旭先生，OCBC中层资本及股权投资部全球主管关昭博先生，Lion X Ventures CEO郭燕妮女士） 郑光廷校长致辞："物理智能将是未来十年重塑人类社会的核心力量。我们选择在这个时刻全力投入这个方向，不只是为了建立一个好的研究组织，而是以我们的视角定义一个新科研领域。我相信，多年后回望今天，这将是科大历史上一个重要的时刻。"学术界、产业界、投资界多方力量汇聚一堂，充分体现了此次合作的高度与影响力。科创中心的成立不仅是校企合作的里程碑，也成为沪港两地科技交流创新的典范。「产研联盟」亮灯现场 「资本联盟」亮灯现场活动现场同时启动了"产研联盟"与"资本联盟"，香港科技大学、天瞳威视以及其他头部机构共同发起了两个联盟。第一批产研伙伴包括：清华大学、微软亚洲研究院、51视界（6651.HK）、沐曦股份（688802.SH）、安谋科技、辉羲智能，本次参与的投资机构有：汇丰（0005.HK）、Lion X Ventures、龙石资本、GPTX简坤资本、德联资本、G70环球家族办公室、微木控股、达武创投，这标志着围绕物理AI的产学研用协同创新生态正式启航。产研联盟将聚焦技术攻关与场景落地，资本联盟则为领先的技术成果提供资金支持和商业化路径。在人才培养层面，双方将共建接轨国际标准的产业实训体系，由天瞳威视提供真实工程场景与产业化实训机会，推动形成从基础研究、技术开发到场景应用的完整生态链所需人才的培养体系。本次港科大物理AI科创中心的成立，将进一步在全球最前沿的物理AI领域推动香港与内地的科技交流与资源整合，联合吸引产业链上下游伙伴，打造开放共赢的物理AI产业新格局。关于香港科技大学香港科技大学（港科大）（https://www.hkust.edu.hk/）是国际知名的大学，致力推动创新教学、卓越研究及具影响力的知识转移。港科大着重为学生提供全面及跨学科的教学，于《2026年 QS 亚洲大学排名》中排行第六，《泰晤士高等教育全球年轻大学排名榜2024》中排行第三，并在《泰晤士高等教育大学影响力排名2025》中全球排第19、全港第一。港科大共有11个学科入选《2026年QS世界大学学科排名》全球50强；此外，在《泰晤士高等教育世界大学学科排名2026》中，涵盖人工智能及机器学习的「计算机科学」领域连续十年蝉联全港第一。此外，港科大在全球大学就业能力排名中，一直位处全球首30名以内，反映毕业生极具竞争力。在研究及创业创新方面，逾八成的科大研究，于香港的大学教育资助委员会最新的「2020研究评审工作」被评为「国际卓越」或「世界领先」水平。截至2026年5月，港科大成员共创立了逾1,900间至今活跃的初创公司，当中包括11间独角兽企业和22间成功退场的公司（上市集资或被并购）。关于天瞳威视苏州天瞳威视电子科技股份有限公司（CalmCar）成立于2016年，是中国领先的以软件为核心的L2-L2+级及L4级驾驶解决方案提供商。按2024年装机量计，公司位居中国第二大同时提供行车与泊车解决方案的软件核心供应商，并率先在海外市场实现L2-L2+级量产方案交付。公司专注于智能驾驶关键技术，产品涵盖行车、泊车、整合驾驶员监测系统的智能座舱解决方案，以及Robobus、Robotruck、Robotaxi及Robosweeper等L4级应用场景，已与超过30 家整车厂展开合作，其中包括2024年中国销量前十强车企中的9家。战略投资者涵盖采埃孚、上汽北美、上汽恒旭、北汽产投、中国联通、地平线、千方科技、商汤科技、Lion X Ventures、华侨银行等头部产业资本，为技术创新与全球化拓展提供坚实支撑。关于Lion X VenturesLion X Ventures是一家立足产业、深耕跨境布局的专业风险投资机构，聚焦东南亚数字经济与高端制造赛道，紧抓中国企业出海东南亚的核心趋势，为高潜力早期及成长阶段企业提供资本、产业资源与全球化落地支持。Lion X Ventures隶属的狮城资本成立于2019年，是专注成长型创新企业的价值型投资机构，亦是数字经济与产业生态联合投资的实践者。机构长期聚焦新一代信息科技、产业数字化、消费科技、先进制造，同时积极布局绿色科技与碳中和赛道。依托东南亚顶级金融集团资源，采用产业龙头联合管理基金模式开展投资，以深度产业视角赋能被投企业，构建中国—东南亚双向联动的产业生态，实现资本、产业与区域发展的多方共赢。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 3, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong University of Science and Technology (HKUST) and Suzhou Calmcar Electronics Technology Co., Limited (CalmCar) yesterday officially signed a strategic agreement to jointly establish the Physical AI Innovation Center. The Center is dedicated to advancing full-stack physical AI technologies, addressing fundamental bottlenecks in current AI, including an insufficient understanding of the laws of the physical world, limited reasoning capabilities, and a lack of reliable support for action and decision-making.The Center will build a new-generation physical AI technology foundation capable of understanding, predicting, reasoning, and decision-making, supporting strategic industries such as autonomous driving, robotics, and smart manufacturing, while helping position Hong Kong as a key strategic hub for national physical AI innovation.Multidimensional Research Directions: Full-Stack Layout from Chips to ApplicationsThe Center will pursue research covering chips and systems, foundational models and data, privacy protection and safety governance, as well as core application scenarios. By exploring and leveraging world models to build high-fidelity strategy validation and interactive reasoning capabilities, the Center aims to train AI in virtual environments before transferring capabilities to the real world-significantly improving AI‘s generalizability, interpretability, and reliability in complex and open environments, and building a long-term technical foundation for a wide range of intelligent applications.The Center’s ambition is to become a global strategic hub for physical AI innovation, leading the development of industry benchmarks and open-source platforms, and cultivating internationally competitive talent in physical AI.Based in Hong Kong, Serving the National “AI+” StrategyThe Center will actively serve the national “AI+” strategy, positioning itself with Hong Kong as its base, the Greater Bay Area as its hinterland, and the world as its stage. It strives to become a strategic highland for physical AI research in the Asia-Pacific region and an international hub for collaboration. The Center will establish end-to-end capabilities from fundamental research to industrial deployment, providing unified technical standards and common tools for the industry. Leveraging Hong Kong’s global connectivity and the Greater Bay Area’s comprehensive industrial supply chain, the Center will accelerate technology transfer and build a world-leading research and innovation center for physical intelligence.World-Class Academic LeadershipThe Center is led by Prof. GUO Song – Fellow of the Canadian Academy of Engineering, Foreign Member of the European Academy of Sciences (EU), IEEE Fellow, and Chair Professor in the Department of Computer Science and Engineering at HKUST – who serves as its director. Prof. Guo has long been engaged in distributed computing, edge AI, and multi-modal foundation models, dedicated to solving the challenges of generalization and reliability of AI in real-world physical environments.He is a recipient of the IEEE Edward J. McCluskey Technical Achievement Award, one of the highest honors in computer engineering, and is widely recognized as an international leader in the field. He also leads the Pervasive Intelligence Laboratory (PeiLAB), which has been based in Hong Kong for a decade and has produced substantial original achievements in physical world modeling, embodied reinforcement learning, and edge intelligent systems, providing a solid theoretical foundation for the Center’s research endeavors. Prof. Guo Song remarked: “Our pioneering ‘Physical Alignment’ technology upgrades generative video models into interactive world models, marking a shift in AI from ‘seeing the world’ to ‘acting on the world.’ By enabling infinite trial and error in virtual spaces, we provide a new paradigm for behavior prediction and safety planning in next-generation autonomous driving.” Prof. Zheng Weimin stated that physical AI will be a major strategic direction following general-purpose foundation models. He then presided over the handshake and group photo ceremony between the Strategic Advisory Committee and the Innovation Center, marking the field’s official entry into a new phase of industry-academia-research integration. He expressed hope that the Center will continue to make significant contribution to the national AI strategy.The Center has invited Prof. ZHENG Weimin—Senior Member of the Chinese Academy of Engineering, 10th President of the China Computer Federation (CCF), and Professor at Tsinghua University—to chair its Strategic Committee. Prof. GUO Yike—Foreign Member of the Chinese Academy of Engineering, Fellow of the Royal Academy of Engineering (UK) and the European Academy of Sciences (EU), and Provost of HKUST—serves as the University Advisor to the Center, providing strong support.Other Strategic Committee advisors include Prof. Xuemin (Sherman) SHEN—Foreign Member of the Chinese Academy of Engineering, Fellow of the Royal Society of Canada, Fellow of the Canadian Academy of Engineering, and Professor at the University of Waterloo; Dr. Bai-ning GUO—Fellow of the Royal Society of Canada, Microsoft Technical Fellow, Managing Deputy Director of Microsoft Research Asia, IEEE Fellow, and ACM Fellow; and Prof. David Atienza ALONSO — Fellow of the European Academy of Sciences, IEEE Fellow, ACM Fellow, Professor of Electrical and Computer Engineering at EPFL, and Associate Vice President for Centers and Platforms at EPFL.From Perception to Understanding: Driving the Evolution of Intelligent SystemsUnlike traditional AI that relies on massive data fitting, physical AI emphasizes a model’s ability to understand dynamic real-world laws and causal structures. Physical AI is driving intelligent systems beyond perception and recognition toward dynamic prediction, interactive reasoning, and autonomous decision-making grounded in physical consistency. As a key enabling technology, world models simulate and anticipate environmental dynamics, providing a foundation for policy learning and validation in complex scenarios while enhancing generalization and reliability in distributed settings.Leveraging the Physical AI Innovation Center, CalmCar—as a co-founder of the Center— will take the lead in applying these technologies to autonomous driving, enabling vehicles not only to perceive their surroundings but also to understand physical causality and anticipate the evolution of traffic scenarios, thereby advancing from perception to cognition.Looking ahead, the Center is committed to building partnerships with a broader range of industry partners, validating and refining physical AI technologies across diverse application scenarios, driving innovation in world model methodologies, and fostering the sustainable integration of physical AI technologies with the industrial ecosystem.Unveiling Ceremony: Witnessed by Leaders from Government, Academia, and IndustryThe unveiling ceremony brought together government leaders, leading academics, industry executives, and investment professionals. Representatives from HKUST and CalmCar’s founding team jointly unveiled the Center. Distinguished guests, including Mr. Duncan CHIU, Legislative Council Member (Technology & Innovation) of Hong Kong, and Mr. CHEN Xu, Executive Deputy Director of the Guangzhou Greater Bay Area Office, witnessed the launch of the initiative.As a core strategic partner in establishing the Center, Lion X Ventures has been deeply involved in its preparation and ecosystem building throughout the process. Leveraging its industry resources, cross-border reach, and capital expertise, Lion X Ventures provides comprehensive support for the Center’s operations and development, laying a solid foundation for its long-term growth.The high-caliber presence of leaders from government, academia, industry, and investment community, combined with the strategic support of top investment institutions, fully demonstrates the Center’s industry standing, resource depth, and strategic value. It also marks the official launch of a collaborative innovation ecosystem in the Greater Bay Area led by HKUST’s physical AI technologies. The HKUST-CalmCar Physical AI Innovation Center inauguration ceremony(From left to right: Ms. Diana WU, CEO of HSBC Hong Kong; Mr. Duncan CHIU, Legislative Council Member (Technology & Innovation) of Hong Kong; Mr. Terry TSANG, HKUST Court Member and Chairman of the Convocation, CEO of Madhead; Prof. ZHOU Xiaofang, Head of the Department of Computer Science and Engineering at HKUST; Prof. ZHENG Weimin, Academician of the Chinese Academy of Engineering, former Chairman of the China Computer Federation, Professor at Tsinghua University; Mr. WANG Xi, Chairman and CEO of CalmCar; Prof. Guo Yike, Provost of HKUST; Prof. Tim CHENG, Vice-President for Research and Development of HKUST; Prof. Guo Song, Chair Professor of the Department of Computer Science and Engineering at HKUST and Director of the Physical AI Innovation Center; Mr. CHEN Xu, Executive Deputy Director of the Guangzhou Greater Bay Area Office; Mr. Daniel KWAN, Global Head of Mid-Capital and Equity Investment at OCBC; Ms. GUO Yanni, CEO of Lion X Ventures) Prof. Tim Cheng stated: “Physical intelligence will be a core force reshaping human society over the next decade. We have chosen this moment to fully commit to this direction—not merely to build a strong research organization, but to define a new research field from our own perspective. I believe that, years from now, when we look back on today, this will be remembered as an important moment in HKUST’s history.”The gathering of leaders from academia, industry, and investment underscores the significance and impact of this collaboration. The establishment of the Center is not only a milestone in university-industry collaboration but also a model for technology exchange and innovation between Shanghai and Hong Kong. The launch ceremony of the Industry-Research Alliance The launch ceremony of the Capital AllianceThe ceremony also marked the launch of the Industry-Research Alliance and the Capital Alliance, jointly initiated by HKUST, CalmCar, and other leading institutions. The inaugural industry partners include Tsinghua University, Microsoft Research Asia, 51WORLD (6651.HK), MetaX Integrated Circuits (688802.SH), Arm China, and Huixi Technology. Participating investment institutions include HSBC (0005.HK), Lion X Ventures, Dragonstone Capital, GPTX Investment, Delian Capital, G70 MFO, WeMove Capital, and Great Filter Venture.This marks the official launch of a collaborative innovation ecosystem spanning industry, academia, research, and application in the field of physical AI.The Industry-Research Alliance will focus on technology breakthroughs and scenario deployment, while the Capital Alliance will provide funding and commercialization pathways for leading technologies. In terms of talent development, both sides will build an industrial training system aligned with international standards, with CalmCar providing real-world engineering scenarios and hands-on opportunities, thereby nurturing a talent pipeline that spans basic research, technology development, and application deployment.The establishment of the Physical AI Innovation Center will further promote technology exchange and resource integration between Hong Kong and the Chinese Mainland in the most advanced frontier of physical AI. It aims to attract partners across the entire industrial chain and create an open, win-win ecosystem for the physical AI industry.About The Hong Kong University of Science and TechnologyThe Hong Kong University of Science and Technology (HKUST) (https://www.hkust.edu.hk/) is a world-class university known for its innovative education, research excellence, and impactful knowledge transfer. With a holistic and interdisciplinary pedagogy approach, HKUST was ranked 6th in the QS Asia University Rankings 2026, 3rd in the Times Higher Education’s Young University Rankings 2024, and 19th globally and 1st in Hong Kong in the Times Higher Education’s Impact Rankings 2025. Eleven HKUST subjects were ranked among the world’s top 50 in the QS World University Rankings by Subject 2026. In addition, in the Times Higher Education World University Rankings by Subject 2026, HKUST’s Computer Science discipline which encompasses areas such as artificial intelligence and machine learning, has been ranked No. 1 in Hong Kong for ten consecutive years. Our graduates are highly competitive, consistently ranking among the world’s top 30 most sought-after employees. In terms of research and entrepreneurship, over 80% of our work was rated “internationally excellent” or “world leading” in the Research Assessment Exercise 2020 of the Hong Kong’s University Grants Committee. As of May 2026, HKUST members have founded over 1,900 active start-ups, including 11 Unicorns and 22 exits (IPO or M&A).About CalmCarSuzhou Calmcar Electronics Technology Co., Limited (CalmCar) was founded in 2016 and is a leading software-focused provider of L2-L2+ and L4 driving solutions in China. By 2024 installation volume, it ranks as the country’s second largest software-focused provider that offers both driving and parking solutions, and the first Chinese provider to deliver mass-production L2-L2+ solutions overseas. The company focuses on key autonomous driving technologies, offering driving, parking, and intelligent cockpit solutions with integrated driver monitoring systems (DMS), as well as L4 applications including robobuses, robotrucks, robotaxis, and robosweepers. CalmCar has partnered with over 30 vehicle manufacturers, including nine of China’s top ten automakers by sales in 2024. Its strategic investors include ZF, SAIC North America, SAIC Hengxu, BAIC Capital, China Unicom, Horizon Robotics, China TransInfo, SenseTime, Lion X Ventures, OCBC, and other leading industry players, providing solid support for innovation and global expansion.About Lion X VenturesLion X Ventures is a professional venture capital institution rooted in industry and focused on cross-border investment. It targets Southeast Asia’s digital economy and high-end manufacturing sectors. Riding on the trend of Chinese enterprises expanding into Southeast Asia, we deliver capital support, industrial resources and global landing solutions for high-potential startups and growth-stage companies.Founded in 2019, Lion Partners is the parent entity of Lion X Ventures. As a value investor dedicated to growth-oriented innovative enterprises, it is also a pioneer in joint investment across the digital economy and industrial ecosystem. We maintain a long-term focus on next-generation information technology, industrial digitalization, consumer tech and advanced manufacturing, while actively expanding our footprint in green technology and carbon neutrality.Backed by resources from leading financial groups in Southeast Asia, we adopt a co-management fund model partnered with industry leaders. With profound industrial insights, we empower portfolio companies and build a two-way interactive industrial ecosystem connecting China and Southeast Asia, ultimately achieving win-win outcomes for capital, industries and regional development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

OTTAWA, ON, June 3, 2026 - (ACN Newswire via SeaPRwire.com) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has executed a non-repayable Contribution Agreement (the "Agreement") with Natural Resources Canada ("NRCan") under the Government of Canada's newly established First and Last Mile Fund ("FLMF"), formerly the Critical Minerals Infrastructure Fund, securing up to $1,378,700 in non-dilutive federal funding (the "Funding") to advance critical transportation and energy infrastructure planning under the Project Titled Lac Knife Graphite Mine Access Road and Hydro Connection (the "Project") for the Company's flagship Lac Knife Graphite Project ("Lac Knife") in northeastern Quebec.The Funding will support engineering, environmental, permitting, community engagement and feasibility activities required to advance the planned all-season access road and Hydro-Quebec grid connection toward a construction-ready, shovel-ready stage. Once completed, these pre-development activities are expected to materially de-risk future infrastructure development and significantly advance Lac Knife's pathway toward future construction, development financing, strategic partnerships and operation.The Funding forms part of the Government of Canada's recently announced C$3.6 billion Critical Minerals Investment Package, unveiled at the 2026 Prospectors & Developers Association of Canada (PDAC) Convention by the Honourable Tim Hodgson, Minister of Energy and Natural Resources. A cornerstone of the package is the C$1.5 billion FLMF, established to advance enabling infrastructure that moves strategic critical mineral projects toward construction readiness while strengthening domestic supply chains and supporting Canada's economic, defence and national security objectives."We are honoured to receive this support from the Government of Canada, which recognizes the strategic importance of the Lac Knife project to the North American critical minerals supply chain," said Dean Hanisch, Chief Executive Officer of Focus Graphite. "As we advance toward permitting and development, this funding is a strong endorsement of Focus Graphite's role in helping build a secure domestic supply of high-grade graphite. We are also fortunate to have existing road and power infrastructure, providing a significant advantage as we move closer to production."Lac Knife hosts one of North America's highest-grade natural graphite deposits and represents a strategically important source of natural graphite for North American and allied supply chains. Natural graphite is a foundational material for lithium-ion batteries, advanced manufacturing, energy storage systems, and a growing range of defence and dual-use technologies, making secure domestic supply increasingly important to Canada and its allies."The objective is simple: advance Lac Knife, reduce risk and preserve shareholder capital," said Jason Latkowcer, Vice President of Corporate Development of Focus Graphite. "Around the world, governments and industry are moving quickly to secure critical mineral supply chains. We've heard that message directly from allies and strategic stakeholders. There isn't time to waste. This funding helps move Lac Knife from planning toward execution. Early technical work has already identified opportunities to improve access, and we expect further optimization as engineering and infrastructure planning advances. This is another tangible step toward building a strategic graphite asset for Canada and its allies."A key component of the program includes collaboration with Indigenous communities, including the Innu Takuaikan Uashat mak Mani-Utenam ("ITUM"). The Project includes the establishment of joint technical and steering committees, Indigenous workforce participation initiatives, skills development programs, community consultation activities and support for Indigenous participation in the future development and operation of the planned infrastructure. These activities align with the objectives of the First and Last Mile Fund to advance Indigenous leadership, engagement and participation throughout the development of strategic critical mineral infrastructure."The development of Lac Knife is a perfect example of Canada's new mining era: a strategic project, developed to benefit local economies, sustainably, and in partnership with Indigenous Peoples, along with advancing Canada's role as a reliable global supplier of critical minerals," said the Honourable Tim Hodgson, Minister of Energy and Natural Resources. "By investing in the infrastructure and early work needed to advance this high-grade graphite project, we are reducing risk, accelerating development, and helping to build a secure, end-to-end supply chain-from mine to market. This is how we strengthen economic and supply chain security for decades to come."The infrastructure initiative is expected to deliver multiple long-term benefits to Canada and Quebec. The proposed access road will establish reliable year-round access to the Lac Knife site, while the future transmission connection will support the electrification of mining operations through Quebec's hydroelectric grid, reducing reliance on diesel-powered infrastructure and strengthening the sustainability, resilience and security of Canada's critical minerals supply chain. The planned infrastructure is expected to support future production, improve regional access and contribute to long-term economic development opportunities across Quebec's North Shore region.Federal Funding DetailsUnder the executed Agreement, NRCan will provide up to C$1,378,700 in non-repayable funding, representing approximately 50% of total eligible Project costs. Focus Graphite will contribute an equivalent amount toward the Project. The Agreement represents another important step in advancing Lac Knife and reinforces Canada's commitment to developing secure domestic critical mineral supply chains from extraction through processing and delivery into North American and allied markets.Funding will support the full work program outlined in the Agreement, including feasibility and engineering studies, environmental baseline work, geotechnical and LiDAR surveys, stakeholder engagement, regulatory and permitting activities and detailed infrastructure design. These activities are expected to culminate in finalized engineering plans, environmental assessments, community approvals and permit applications required to support future construction decisions.The Project is scheduled to continue through March 2028.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures an eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comLinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things: the anticipated receipt and use of funding under the Contribution Agreement with Natural Resources Canada; the completion of the activities contemplated under the Lac Knife Graphite Mine Access Road and Hydro Connection Project; the advancement of the Lac Knife Graphite Project toward construction-ready and shovel-ready status; the completion of engineering, environmental, permitting, stakeholder engagement and feasibility activities; the anticipated benefits of the planned access road and Hydro-Québec grid connection; the Company's ability to secure required approvals, permits and community support; the timing and completion of the Project work program; the potential for future development financing, government funding, strategic partnerships and offtake arrangements; the future development, construction and operation of the Lac Knife Project; the role of Lac Knife in supporting domestic and allied critical mineral supply chains; and the Company's ability to pursue additional non-dilutive funding opportunities and execute its long-term development strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299885 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Astana, Kazakhstan, Jun 2, 2026 - (ACN Newswire via SeaPRwire.com) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong Trade Development Council (HKTDC), began its visit to Astana, the capital of Kazakhstan, on 1 June. During the visit, a total of 43 memoranda of understanding (MoUs) and announcements were signed, covering areas including trade and commerce, investment, financial services, technology, aviation, and green finance. These agreements further strengthened trade, economic and industrial cooperation among Hong Kong, Chinese Mainland and Kazakhstan, fully leveraging Hong Kong’s unique role as the country’s two-way services platform and supporting enterprises in tapping opportunities in Central Asia.The delegation will conclude its Kazakhstan visit tomorrow and depart for Uzbekistan to further explore business and trade cooperation among Hong Kong, Chinese Mainland and Central Asian countries under the Belt and Road Initiative.To promote business collaboration, the HKSAR Government and the HKTDC jointly hosted a business luncheon today, attracting more than 300 business leaders and senior officials.John Lee, the Chief Executive of the HKSAR, said at the luncheon: “Kazakhstan has, for centuries, connected Eastern and Western civilisations, serving as a bridge of commerce, culture and innovative ideas. That legacy continues today. From the port of Khorgos to the Trans-Caspian International Transport Route, Kazakhstan is now a business and logistics hub linking China, our country, and Europe. Rich in oil and mineral resources, and rapidly developing and diversifying, Kazakhstan is a regional economic powerhouse. Hong Kong, a pivotal player in the Belt and Road Initiative, looks forward to working with Kazakhstan in creating mutual opportunities.”Prof Frederick Ma, Chairman of the HKTDC, said: “Kazakhstan is the largest economy in Central Asia, accounting for 53% of the region’s GDP in 2025. Under its Kazakhstan 2050 Strategy, the country is actively promoting economic diversification, with the goal of becoming one of the world’s top 30 most developed economies by 2050, demonstrating strong growth potential. This visit has enhanced local enterprises’ understanding of Hong Kong’s advantages as a superconnector and super value-adder. Under the Belt and Road Initiative, we believe substantial cooperation opportunities will emerge across various sectors, including logistics infrastructure, green finance, digital economy, agricultural upgrading and food processing. The model of Mainland enterprises going global with Hong Kong while leveraging the HKTDC platform will create new opportunities for collaboration with Central Asia.”Following previous visits to Qatar and Kuwait last year, this delegation once again brings together the strengths of Hong Kong and Mainland enterprises. The delegation comprises 70 business leaders from Hong Kong and enterprise representatives from 17 provinces and municipalities across the Chinese Mainland, covering a wide spectrum of sectors, including financial and professional services, logistics and transportation, innovation and technology, trade, green industries, energy and mining, biopharmaceuticals, the automotive industry as well as the media. For the first time, representatives from journalism associations, including The Newspaper Society of Hong Kong and the Hong Kong News Executives’ Association, have joined the delegation, in line with the Policy Address’s initiative to enable local media to develop their overseas network and tell the Hong Kong story.During their stay in Kazakhstan, the delegation met with senior representatives from government bodies, chambers of commerce and major corporations, including the National Chamber of Entrepreneurs of the Republic of Kazakhstan ‘Atameken’, ‘Baiterek’ National Investment Holding, Halyk Bank and Samruk-Kazyna. They exchanged views on strengthening bilateral trade ties and industrial collaboration and explored opportunities to leverage Hong Kong as a platform for broader regional cooperation.The delegation also visited Astana Hub and the Astana International Financial Centre (AIFC) to gain insights into the latest developments in innovation and technology as well as financial services in Kazakhstan.According to available data, Kazakhstan’s GDP is projected to grow by 4.6% in 2026, reaching approximately US$360.5 billion, to maintain its position as the largest economy in Central Asia and among the world’s top 50 economies. Uzbekistan’s GDP is forecast to grow by 6.5% in 2026, reaching approximately US$181.5 billion, with its GDP in US dollar terms having doubled between 2017 and 2025. Overall, the IMF forecasts GDP growth for Central Asia and the Caucasus at 6.2% in 2025 and 4.8% in 2026, higher than the global average of 3.1%. During its Kazakhstan visit, the delegation facilitated 43 MoUs and announcements, including:1.Hong Kong Trade Development Council (HKTDC) and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"2.Hong Kong Trade Development Council (HKTDC) and Astana International Financial Centre (AIFC)3.Hong Kong Trade Development Council (HKTDC) and Satbayev University4.Airport Authority and Almaty International Airport5.Belt and Road General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"6.Belt and Road General Chamber of Commerce and Commex HK Link Digital Trading Company Limited and Eurasian Trading System Export” International Commodity Exchange (ETSE)7.Belt and Road General Chamber of Commerce and JINGSH CONSULTING LLP8.Chinese Manufacturers Association and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"9.Cyberport and Astana Hub10.Federation of Hong Kong Industries (FHKI) and Ministry of Artificial Intelligence and Digital Development in Kazakhstan11.Hong Kong Exchange and Clearing Limited and Astana International Exchange (AIX)12.Hong Kong Exchange and Clearing Limited and Astana International Financial Centre (AIFC)13.Hong Kong Science and Technology Parks and Astana Hub14.Hong Kong-Shenzhen Innovation and Technology Park Ltd. and Astana Hub15.The Hong Kong General Chamber of Commerce and National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken"16.Law Society of Hong Kong and National Bar Association of Kazakhstan17.BOCHK and Bank of China Kazakhstan and Baiterek18.BOCHK and Bank of China Kazakhstan and Samruk Kazyna19.Bosera International Asset Management Limited and JSC "Halyk Bank of Kazakhstan"20.Cathay Pacific and Almaty International Airport and Almaty City Government (Tourism Development)21.China International Capital Corporation Limited and Freedom Holdings22.China International Capital Corporation Limited and Samruk Kazyna23.China International Capital Corporation Limited and Astana International Financial Centre (AIFC)24.China International Capital Corporation Limited and Air Astana25.Deloitte and Universal Energy Co., Ltd.26.Ewpartners Investment Management Limited and Dasco Capital Ltd.27.Ewpartners Investment Management Limited and Astana International Financial Centre (AIFC)28.Goldford Group and Gas Energy Solution LLP29.Hong Kong News executives’ Association and The Newspaper Society of Hong Kong and Khabar Agency JSC30.Jardine Matheson and KIDF31.Jiaxin International Resources Investment Limited and Industry and Construction of the Republic of Kazakhstan32.Koln 3D Technology (Medical) Limited and Kazakh Research Institute of Oncology and Radiology33.PCCW and Kazakhtelecom34.PCCW and Khabar Agency JSC35.SCMP and Astana International Financial Centre (AIFC)36.SCMP and GOBI PARTNERS and Astana Hub and Khan Tengri Innovation Hub37.Soy-Sky FarmTech Company Limited (Hong Kong) and JSC NC Food Contract Corporation of Kazakhstan38.Standard Chartered Bank and Development Bank of Kazakhstan39.Templewater and Freedom Holdings40.The Standard and Freedom Horizons41.Standard Chartered Bank and Hangzhou CIEC Group Co., Ltd.42.Walvax Biotechnology Co., Ltd. and Gold Astrum LLC43.Ewpartners Investment Management Limited and Jiangsu Solicitude Medical Technology (Group) Limited and Samruk-Kazyna Invest LLPIn addition, during the Central Asia visit, non-delegation members also signed a number of MoUs in academic, cultural or other collaboration areas:1.A-Grade Energy Ltd and Ministry of Artificial Intelligence and Digital Development of the Republic of Kazakhstan2.A-Grade Energy Ltd and Freedom Holdings3.China Mobile International Limited and Qazpost-YTO4.HKT and Education University of Hong Kong5.City University of Hong Kong and JSC "Center for International Programs under the Ministry of Science and Higher Education of the Republic of Kazakhstan6.City University of Hong Kong and Satbayev University7.Education University of Hong Kong and Nazarbayev University8.Hong Kong Polytechnic University and Nazarbayev University9.Thei and BILIM-INNOVATION International Social Foundation10.Thei and L.N. Gumilyov Eurasian National UniversityPhoto download: https://bit.ly/49zcFUnDuring its visit to Kazakhstan, the delegation facilitated 43 memoranda of understanding (MoUs) and announcementsTo promote business collaboration, the HKSAR Government and the HKTDC jointly hosted a business luncheon, attracting more than 300 local business leaders and senior officials. John Lee, the Chief Executive of the HKSAR, said at the luncheon: “Kazakhstan has, for centuries, connected Eastern and Western civilisations, serving as a bridge of commerce, culture and innovative ideas. That legacy continues today. From the port of Khorgos to the Trans-Caspian International Transport Route, Kazakhstan is now a business and logistics hub linking China, our country, and Europe. Rich in oil and mineral resources, and rapidly developing and diversifying, Kazakhstan is a regional economic powerhouse. Hong Kong, a pivotal player in the Belt and Road Initiative, looks forward to working with Kazakhstan in creating mutual opportunities.”Prof Frederick Ma, Chairman of the HKTDC, said at the luncheon: “Kazakhstan is the largest economy in Central Asia, accounting for 53% of the region’s GDP in 2025. Under its Kazakhstan 2050 Strategy, the country is actively promoting economic diversification, with the goal of becoming one of the world’s top 30 most developed economies by 2050, demonstrating strong growth potential. This visit has enhanced local enterprises’ understanding of Hong Kong’s advantages as a superconnector and super value-adder. Under the Belt and Road Initiative, we believe substantial cooperation opportunities will emerge across various sectors, including logistics infrastructure, green finance, digital economy, agricultural upgrading and food processing. The model of Mainland enterprises going global with Hong Kong while leveraging the HKTDC platform will create new opportunities for collaboration with Central Asia.”The delegation visited Astana Hub to gain insights into the latest developments in the innovation and technology sectorMedia enquiriesHKTDC’s Communications & Public Affairs Department:Johnny Tsui Tel: (852) 2584 4395 Email: johnny.cy.tsui@hktdc.orgSerena Cheung Tel: (852) 2584 4272 Email: serena.hm.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Queensland, Australia, June 2, 2026 - (ACN Newswire via SeaPRwire.com) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has submitted an additional application to the United States Environmental Protection Agency ("EPA") for the manufacture and sale of graphene and graphene coatings (THERMAL-XR®), lubricants (G® LUBRICANT) and other graphene fluids in the United States.GMG has submitted a Significant New Use Notice ("SNUN") to the US EPA under pre-manufacture notice (PMN) P-25-0018. Under this application, GMG is seeking authorisation to manufacture, distribute, sell, use and dispose of graphene and graphene coatings, lubricants and fluids across multiple industries in the United States. GMG expects to obtain this approval by the end of June 2027.This application is in addition to the existing approval under PMN P-25-0018, which authorises the Company to export, distribute, sell, use and dispose of graphene coatings across multiple industries in the United States.Craig Nicol, CEO & Managing Director of the Company, commented: "Submitting the SNUN is a decisive step in our US strategy. This application, if approved, will grant GMG the authorisation to manufacture graphene domestically in the United States — not simply to export into the market, but to produce within it. That distinction matters. It positions GMG to serve US customers at scale, deepen our industrial footprint, and build a genuinely American supply chain for graphene-enabled products. We expect EPA approval by the end of June 2027 and are planning our commercial operations accordingly."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "The United States is the most important market in the world for what GMG is building. This SNUN filing reflects our commitment to America — not just as a customer base, but as a centre of production, capital formation, and long-term growth. We are looking to the US to drive the next chapter of GMG's commercial expansion."About THERMAL-XR®:THERMAL-XR® ENHANCE coating system is a unique method of improving the conductivity of corroded heat exchange surfaces and improving and maintaining the performance of new units at peak levels. The process coats and protects heat exchange surfaces while improving and rebuilding the lost corroded thermal conductivity and increasing the heat transfer rate by leveraging the physics of GMG Graphene, resulting in an efficiency improvement and a potential power reduction. THERMAL-XR® ENHANCE is now patented for 20 years in Australia and is expected to be patented in other countries around the world.About G® LUBRICANT:G® LUBRICANT is what management believes to be a transformative graphene liquid concentrate additive designed to enhance the performance of diesel and gasoline (petrol) engines. This product has the potential to reshape the future of the global liquid fuels industry and offers an innovative solution that optimises efficiency and power for stationary or mobile engines. G® LUBRICANT, a graphene liquid concentrate that can be added to any mineral or synthetic oil used in an internal combustion engine in a 1:100 dosage, has been verified by the University of Queensland to increase fuel efficiency by up to 8.4% in a diesel engine, as announced in February 2025.1 G® LUBRICANT is now patented for 20 years in Europe, the US, and China.1RSU GrantsThe Company is also pleased to announce that following the annual remuneration review, its Board of Directors have approved the grant of an aggregate of 783,590 Restricted Share Units ("RSUs") to employees and directors of the Company pursuant to its Restricted Share and Performance Share Plan and the Stock Option Plan.When vested, each RSU entitles the holder thereof to receive one Share upon exercise in accordance with the Plan. The holder at their own discretion, and separately to the Company, may action those shares accordingly for their personal use.About GMG:GMG is an Australian-based clean-technology company that develops, manufactures and sells energy-saving and energy-storage solutions, enabled by graphene produced via its in-house production process. GMG uses its proprietary process to decompose natural gas (i.e., methane) into its natural elements — carbon (as graphene), hydrogen, and some residual hydrocarbon gases. This process produces high-quality, low-cost, scalable, tuneable, and low- to no-contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities and to secure market applications. In the energy savings segment, GMG has initially focused on a graphene-enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating), which is now being marketed into other applications including electronic heat sinks, industrial process plants, and data centres. GMG has also developed a graphene lubricant additive focused on saving liquid fuels, initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively, with financial support from the Australian Government, to progress R&D and commercialisation of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes", "expects" or "anticipates", or variations of such words and phrases, or statements that certain actions, events or results "may", "could", "should", "would", or "will" "potentially" or "likely" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include, without limitation: GMG's ability to obtain EPA authorisation to manufacture, distribute, sell, use and dispose of graphene and graphene coatings, lubricants and fluids across multiple industries in the United States; GMG's expectation to obtain SNUN approval by the end of June 2027; and GMG's intention to progress its broader US commercialisation activities across its graphene product portfolio; GMG's intentions to develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialization of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and GMG's critical business objectives.Such forward-looking statements are based on a number of assumptions of management, including the receipt of EPA approval of the SNUN filing. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors that may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation, that GMG does not receive, or does not receive on a timely basis, EPA approval of the SNUN, and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025, available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except as required by applicable securities laws.1 GMG, "GMG Unveils G® LUBRICANT Engine Performance Testing Results," February 2025, https://graphenemg.com/gmg-unveils-g-lubricant-engine-performance-testing-results-a-transformative-graphene-energy-saving-solution-for-the-multi-trillion-dollar-global-liquid-fuel-industry/To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299808 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia, June 2, 2026 - (ACN Newswire via SeaPRwire.com) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (WKN: A1W038) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce that it has appointed Canaccord Genuity Corp. ("Canaccord Genuity") as financial advisor in connection with a formal strategic review process (the "Review"). The Review has been initiated by Doubleview with a primary focus on potential sales of the Company, with a view to maximizing shareholder value.The Review will explore and evaluate a broad range of strategic and financial options, which may include a potential sale of the Hat Project or other near-term alternatives, a merger, amalgamation, plan of arrangement, joint venture, business combination, recapitalization, special dividend, strategic investments (including potential participation from government-backed entities and sovereign wealth funds), or such other transaction as the Board determines is in the best interests of the Company and its shareholders.Canaccord Genuity will provide comprehensive advisory services throughout the Review, including financial analysis and valuation, transaction structuring, merger modelling, negotiation support, market monitoring, and, if requested by the Board, fairness opinions. The engagement also provides Doubleview with access to Canaccord Genuity's extensive global network of strategic and financial counterparties across the gold, copper, and critical minerals sectors.Farshad Shirvani, President and CEO of Doubleview Gold Corp., commented:"The Hat Project has delivered a robust Preliminary Economic Assessment with an after-tax NPV(5%) ranging from C$6.73 billion to C$7.27 billion at consensus metal prices and C$13.53 billion to C$14.85 billion at spot metal prices, and an IRR ranging from 19% to 39%, demonstrating exceptional economics and significant critical-minerals exposure, including potential value contribution from a scandium and cobalt recovery circuit. Engaging Canaccord Genuity to lead a formal strategic review process allows the Board to thoroughly and independently evaluate all available options to unlock the full value of the Hat Polymetallic Project in British Columbia's Golden Triangle for the benefit of our shareholders and stakeholders. We believe the current strong commodities environment and the global focus on critical minerals supply security make this an opportune moment to pursue this process."The Company cautions that the Hat Project Preliminary Economic Assessment is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the results of the Preliminary Economic Assessment will be realized.Qualified Persons:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the technical contents of this news release. He is not independent of Doubleview as he is a shareholder in the company.Review Process and TimingThere is no defined timetable for the completion of the Review. The Company does not intend to make further public announcements regarding the Review unless and until such a disclosure is required. The Company cautions that there can be no assurance that the Review will result in any transaction or, if a transaction is undertaken, as to the terms, structure, timing, or completion of such transaction.About the Hat ProjectThe Hat Project is a polymetallic copper-gold-cobalt-scandium project located in northwestern British Columbia. The project hosts a porphyry-style mineralized system and has been the subject of extensive drilling, geological modelling, metallurgical work, and technical studies. Doubleview continues to advance the Hat Project through exploration, technical evaluation, metallurgical test work, and environmental baseline programs.About Doubleview Gold CorpDoubleview Gold Corp., a mineral resource exploration and development company, is based in Vancouver, British Columbia, Canada, and is publicly traded on the TSX-Venture Exchange [TSX-V: DBG], [OTCQB: DBLVF], [GER: A1W038], [Frankfurt: 1D4]. Doubleview identifies, acquires and finances precious and base metal exploration projects in North America, particularly in British Columbia. Doubleview increases shareholder value through acquisition and exploration of quality gold, copper and silver properties and the application of advanced state-of-the-art exploration methods. The Company's portfolio of strategic properties provides diversification and mitigates investment risks.On behalf of the Board of Directors,Farshad Shirvani, M.Sc. GeologyPresident & Chief Executive OfficerFor further information please contact:Doubleview Gold Corp, Vancouver, BC Farshad Shirvani, President & CEOT: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." Forward-looking information involves known and unknown risks, uncertainties, and other factors which might cause actual results, performance, or achievements to differ from those expressed or implied by such information. There is no assurance the forward-looking information will occur. Statements hereto include the results of the Preliminary Economic Assessment for the Hat Project; the estimation of mineral resources; metal prices; the after-tax NPV and IRR of the Hat Project and references to exploration, technical evaluation, metallurgical test work, and environmental baseline programs. Future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of.Additional forward-looking information in this news release, includes references to the strategic review process and in particular, a potential sale of the Hat Project or other near-term alternatives, a merger, amalgamation, plan of arrangement, joint venture, business combination, recapitalization, special dividend, strategic investments (including potential participation from government-backed entities and sovereign wealth funds). There is no guarantee or certainty that there will be a potential sale of the Hat Project or other near-term alternatives, a merger, amalgamation, plan of arrangement, joint venture, business combination, recapitalization, special dividend, strategic investments (including potential participation from government-backed entities and sovereign wealth funds). Further, there is no guarantee that Canaccord Genuity's advisory services will provide any benefit to the Company or that its extensive global network of strategic and financial counterparties across the gold, copper, and critical minerals sectors will bring any benefit to the Company. Accordingly, readers are advised not to place undue reliance on forward-looking information. Even if a sale or near-term alternative agreement were reached, its completion would be subject to significant risks including the possibility that any necessary regulatory or shareholder approvals would not be obtained, or that any conditions to completion would be achieved. Readers are cautioned to consider these risks when evaluating this information.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299788 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 2, 2026 - (ACN Newswire via SeaPRwire.com) - China’s leading toy brand 52TOYS officially opened a new store at Hong Kong International Airport. Located at Shop 7E101A, Level 7 Departures East Hall (Restricted Area), Terminal 1 of Hong Kong International Airport, a core global transportation hub, the store features thoughtful design and a differentiated product matrix, creating a toy space that offers both trendy texture and cultural warmth, thereby meeting the needs of global travelers and serving as an important window for the brand in the international market.Airport-Inspired Design Creates an International Benchmark StoreThe Hong Kong Airport store follows the brand’s airport flagship store design style, forming a north-south pairing with the Beijing Capital International Airport store as the brand’s dual international “image ambassadors”. It adopts a unique retro terminal style design, comprehensively shaping a trendy cultural base with both retro temperament and future imagination through its spatial structure, material selection, and the integration of terminal elements.In terms of spatial composition, the intertwining and combination of geometric volumes creates a strong architectural sense, paired with light and shadow to create a dynamic futuristic vibe. In terms of materials, the rough concrete texture collides with the cold metal finish, injecting the hardcore texture of industrial style into the retro backdrop and strengthening the atmosphere of the trendy base. Terminal elements such as airplane turbines and runways are cleverly integrated, continuing and strengthening the airport’s sense of place, which adds a different kind of trendy fun to travelers’ journeys, allowing passengers to enjoy a unique travel experience during their waiting time and unlock a brand-new airport leisure experience.The Hong Kong Airport store saw strong visitor traffic and robust sales on its opening day, demonstrating the strong market appeal of the 52TOYS brand and product portfolio. Customers on site commented, “It’s such a great store — it really killed the boredom of waiting for my flight!”, while others said, “There are so many impressive products that I want to pack them all into my suitcase.”Differentiated Product Mix and Signature Displays Deliver a Travel Experience Full of SurprisesThe store is carefully planned around airport travel scenarios and the needs of different consumer segments. At the entrance, a product zone for POUKAPOUKA neck pillows and plush cushions is specially set up, directly matching the essential travel needs. Further inside, themed zones dedicated to popular proprietary IPs including POUKAPOUKA, NOOK and CiCiLu feature scenario-based displays alongside new products. Special IP introduction signage has also been installed to vividly present the spiritual core of the IPs.The store offers a rich and highly layered product portfolio with particularly strong differentiation advantages. According to the store manager, leveraging the unique passenger traffic profile of Hong Kong International Airport, 52TOYS' products with Chinese cultural characteristics, such as the Hyper-Activated and BEASTBOX series, have become highly popular among overseas consumers as sought-after Chinese-style souvenirs. Large-scale collectible figures with strong display and gifting value have also proven especially popular, further demonstrating the brand’s strengths in product portfolio and its broad consumer reach.In addition, the store has launched multiple Hong Kong Airport-exclusive products, including POUKAPOUKA pineapple bun magnetic stickers, hooded neck pillows, and luggage tags, as well as LITTLE BUNS Hong Kong Kung Fu Journey magnetic stickers and Panda Roll Hong Kong Cha Chaan Teng series magnetic stickers. Fusing Hong Kong local culture with practical travel attributes, these products serve both as meaningful travel keepsakes and highly distinctive city souvenirs, highlighting the brand’s deep understanding of segmented consumer scenarios and consumer mindset.Strengthening Presence Across Key Hong Kong and Macau Gateway Hubs to Reinforce a New Global Development LandscapeAs one of the world’s busiest aviation hubs, Hong Kong International Airport connects more than 200 destinations worldwide and brings together an international, high-net-worth and highly mobile consumer base, making it a prime gateway for brands seeking to expand into international markets. Following the opening of the Studio City Macau brand store in November 2025 and the Beijing Capital International Airport store in February 2026, the launch of the Hong Kong Airport store marks the official completion of 52TOYS’ strategic presence across key transportation hubs in mainland China, Macau, and Hong Kong, further adding a critical pillar to the company’s international offline expansion strategy.Industry observers noted that the Hong Kong Airport location is expected to bring three major areas of incremental value to 52TOYS. Firstly, it enables the company to secure a position within the global traffic hub and efficiently reach consumers worldwide through Hong Kong International Airport’s extensive international connectivity, accelerating global expansion. Secondly, it provides access to high-net-worth consumer groups through the airport’s premium passenger structure, creating a new growth engine for offline retail while further enhancing brand influence. Thirdly, it establishes an international brand image showcase, using the airport store as a signature brand window to amplify the global influence of the IP portfolio and further promote Chinese toy culture internationally.Having deeply cultivated the toy industry for many years, 52TOYS continues to strengthen its refined offline layout and innovate across consumer scenarios. From core commercial districts to transportation hubs, and from the domestic market to global expansion, the company continues to integrate toys into consumers’ everyday lifestyles. Looking forward, 52TOYS will use the Hong Kong Airport store as a new starting point to accelerate its international expansion, connecting with consumers worldwide through diversified high-quality IPs and products while further unleashing the vitality of Chinese toy culture in the global market. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 2, 2026 - (ACN Newswire via SeaPRwire.com) - uSMART Securities Limited (“uSMART Securities” or the “Company”), the No.1 Hong Kong Funded Fintech Brokerage^, is pleased to announce the grand opening of uSMART Cafe, a brand-new concept space located in the core district of Kai Tak. The opening marks an innovative integration of fintech and lifestyle experiences, while extending our service network into an emerging community. By extending our service network into the emerging Kai Tak community, we reaffirm our commitment to serving Hong Kong residents with greater accessibility and care. As Kai Tak continues to develop into one of Hong Kong’s key residential and commercial districts, the opening of uSMART Cafe introduces an innovative concept that helps enhance the district’s financial service offerings, providing residents with a more convenient, professional and client-centric wealth management experience.uSMART Cafe Located in Kai Tak: A New Experience Combining Smart Finance with LifestyleuSMART Cafe allow visitors to collectively relive the glory days of Hong Kong’s “The Greed of Man” era and experience the 1980s “red jacket” trading floor scene, we have specially designed uSMART Cafe as a nostalgic finance-themed photo spot. Featuring multiple photo areas and physical stock certificate memorabilia, the cafe seamlessly combines nostalgia with modern lifestyle elements. This creates a brand-new landmark that brings together financial exchange and leisure lifestyle, allowing clients to enjoy coffee and relaxation while experiencing the historical atmosphere of Hong Kong’s stock market.Branch Network Across Hong Kong as Expansion ContinuesAt present, uSMART strategically operates 11 branches in Hong Kong, covering key districts across Hong Kong Island, Kowloon and the New Territories. We remain proactive and open-minded in expanding its physical service centers. At this point, uSMART Cafe aims to combine quality coffee with professional financial services, meeting clients’ diversified wealth management needs in a relaxed and comfortable environment. Looking ahead, uSMART will flexibly adjust its expansion strategy in response to overall operational conditions, market demand and customer feedback. As a leading technology brokerage rooted in Hong Kong with a global outlook, uSMART will continue to leverage our strengths, including the innovative technology capabilities and diversified cross-market investment products, to enhance its products and service experience and meet the needs of different clients.(From left to right: Executive Director of Research – Dickie Wong, Marketing Director – Carrie Wong, Senior Business Development Manager – Bobby Leung)Approval to Provide Virtual Asset Trading Services, Expanding into “Traditional Finance + Virtual Assets”At the opening ceremony, Mr. Dickie Wong, uSMART’s Executive Director of Research, said: “uSMART Securities has received approval from the Securities and Futures Commission of Hong Kong (SFC) to provide virtual asset trading services to eligible clients under its Type 1 regulated activity license for dealing in securities, officially entering the virtual asset sector. We have always committed combining the solid foundation of traditional finance with the innovative power of fintech. Clients can now trade traditional securities and virtual assets on the same platform, that significantly enhancing investment efficiency and convenience. Together with our newly launched futures business, as well as our existing securities and asset management businesses, this creates strong synergies and positions uSMART as one of the few leading technology brokerages in Hong Kong capable of providing both traditional securities trading and virtual asset investment services.”Self-developed SMARTclaw Integrates AI Technology to Create a 24/7 Intelligent Investment AssistantIn addition, uSMART has self-developed the SMARTclaw invest tool, which deeply integrates, as known as “Openclaw”. By apply advance AI technology to intelligent investment scenarios, SMARTclaw is designed to support investors with more efficient market monitoring and data analysis.Compared to general AI solution appears in the market, SMARTclaw is emphasised to the financial investment sector. It is capable to provide more precise and professional market analysis. User can monitor markets and organise data 24/7 by prompting with text, voice recognition as well as scheduling instruction based on their needs. It strategically allows user solving the problems like inability monitoring and filtering large volume information at once while helping users track market data and market movements in order to capture any investing chances.In the future, SMARTclaw is expected to further tailor dedicated investment strategies based on clients’ portfolio data, supporting a more comprehensive intelligent wealth management experience.Looking ahead, uSMART will continue to leverage its fintech advantages by combining AI-powered intelligent investment research tools, diversified investment products, 24/7 online customer service and support from physical service centres. Through these efforts, the Company aims to elevate the industry standard for product and service experience, professional, secure and efficient one-stop investment service platform to help clients capture opportunities across global markets.^"No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of April 2026.About uSMART:uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past eight years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platform, uSMART HK APP supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai, Shenzhen and Hong Kong stock connect), US options, ETF, Funds, Bonds, Asset Management, Futures and more diverse trading services. Furthermore, uSMART also customize services for ultra-high-net-worth individuals, families and enterprise creating comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.comMedia Enquiries:Carrie WongTel: 9788 4665Email: carriewong@usmart.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月2日 - (亚太商讯 via SeaPRwire.com) - 港资科技券商 No.1^ uSMART盈立证券有限公司（下称「盈立证券」或「本公司」）今日欣然宣布，坐落于启德核心地段的全新概念空间「uSMART Cafe」盛大开幕，标志着金融科技与生活品味的创新融合，这次将服务点延伸至新兴小区，更象征我们对服务香港居民的坚定承诺。启德作为香港新兴重点小区，人口持续增长，惟区内金融服务配套尚待完善，uSMART Cafe的落成，正是希望以创新概念填补新小区的金融服务缺失，让居民享受优质、便捷、贴心的理财体验。「uSMART Cafe」进驻启德：理财与生活创新体验为让大家集体重温「大时代」的辉煌年代，感受80年代「红背心出市」的场景，我们特意打造uSMART Cafe为怀旧金融风格打卡店，设有多个打卡位及实体股票纪念品，将怀旧情怀与现代生活品味巧妙结合，打造一个集理财交流及休闲生活于一体的全新地标，让客户在享受咖啡与休闲的同时，亦能感受香港股市的历史氛围。分行遍布全港 继续积极扩张目前，盈立证券在港合共设有11间分行，全面覆盖港九新界核心区域。公司对拓展实体服务中心持积极开放的态度，uSMART Cafe 期望结合优质咖啡与专业金融服务，在轻松舒适的环境下满足客户多元化的财富管理需求，未来公司将因应整体营运情况、市场需求及客户反馈，灵活调整拓展策略。作为扎根香港、面向全球的领先科技券商，盈立证券将以自身优势，包括平台的创新科技能力及跨市场的多元化投资产品，持续优化产品与服务体验，满足不同客户的需求。左起: 盈立证券研究部执行董事 - 黄德几先生、盈立证券香港市场部总监 - 黄晓霖小姐、盈立证券业服拓展经理 - 梁润宝先生获批提供虚拟资产交易服务 布局「传统金融+虚拟资产」盈立证券研究部执行董事 黄德几先生 (Dickie) 在开幕典礼上表示：「盈立证券获得香港证券及期货事务监察委员会（SFC）批准，在第1类受规管活动牌照（证券交易）的基础上，向合资格客户提供虚拟资产交易服务，正式进军虚拟资产领域。我们一直致力将传统金融的稳健基础与金融科技的创新力量相结合，客户可以在同一个平台一站式交易传统证券及虚拟资产，无需切换平台，大大提升了投资效率与便利性。配合刚推出的期货业务，以及固有的证券、资产管理等业务，形成强大的协同效应，成为香港少数能够同时提供传统证券交易与虚拟资产投资服务的领先科技券商。」自创SMARTclaw融合AI技术 打造24/7智能投资助手此外，盈立证券更自家研发SMARTclaw投资工具，深度整合近期风靡全球的AI智能项目OpenClaw（「AI 小龙虾」），将先进AI技术全面应用于智能投资场景。与市面上一般的通用型AI不同，SMARTclaw是专注于金融投资领域的专家级AI，能提供更精准、更专业的市场分析，用户可根据自身投资需求设定指令，包括使用文字及语音识别方式，安排AI机器人7×24小时监控市场及整理数据，甚至执行定时指令，有效解决投资者无法长时间盯盘及信息筛选效率低等问题，协助持续追踪市场数据与异动，及时捕捉投资机会。未来，SMARTclaw更可根据客户的持仓数据，量身定制不同的专属投资策略，实现真正全方位的智能财富管理。盈立证券更特别强化了AI工具使用环境的安全性，严格规范AI执行任务的权限，全方位保护用户隐私与交易安全，让客户更安心使用。展望未来，盈立证券将发挥金融科技优势，结合AI 智能投研工具、多元化投资产品，及7×24小时在线客服、实体服务中心支持，提升行业产品与服务体验的水平，打造专业、安全、高效的一站式投资服务平台，助客户把握全球市场机遇。^「港资科技券商No.1」是取自捷利金融云截至2026年4月为止连续超过一年数据， uSMART盈立证券为香港本地港资互联网券商月成交总额排行第1。关于uSMART盈立证券 ：盈立证券是一间领先科技港资券商，成立于2018年，8年来凭借卓越的战略规划和创新能力，致力于将科技与金融深度融合，业务范围涵盖证券、资产管理、财富管理等领域，为全球投资者独家研发了金融证券交易平台uSMART HK APP，支持港股、美股、A股（沪深港通）、美股期权、ETF、基金、债券、资管和期货等多元化的投资交易服务，此外更为超高净值个人与家族、企业提供度身订制服务，打造全方位综合性资产管理解决方案。详情可浏览https://hk.usmartglobal.com传媒查询： 黄晓霖 Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com